La Jolla Pharmaceutical Company (NASDAQ:LJPC) rose 10.3% during trading on Monday . The company traded as high as $33.13 and last traded at $32.79, with a volume of 616,031 shares changing hands. The stock had previously closed at $29.72.

LJPC has been the subject of a number of recent analyst reports. Chardan Capital restated a “buy” rating and issued a $85.00 price objective on shares of La Jolla Pharmaceutical in a research report on Tuesday, August 8th. Jefferies Group LLC restated a “buy” rating and issued a $40.00 price objective on shares of La Jolla Pharmaceutical in a research report on Tuesday, July 25th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $57.00 price target on shares of La Jolla Pharmaceutical in a research report on Monday, May 22nd. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Thursday, June 29th. Finally, BidaskClub upgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $51.67.

The stock’s 50 day moving average price is $31.27 and its 200-day moving average price is $29.49. The company’s market capitalization is $759.04 million.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.12) by $0.09. La Jolla Pharmaceutical had a negative net margin of 12,692.37% and a negative return on equity of 91.66%. During the same quarter in the prior year, the business posted ($0.90) earnings per share. Analysts anticipate that La Jolla Pharmaceutical Company will post ($4.95) earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc raised its position in shares of La Jolla Pharmaceutical by 11.6% in the second quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 462 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of La Jolla Pharmaceutical during the first quarter worth $195,000. Teza Capital Management LLC bought a new position in shares of La Jolla Pharmaceutical during the first quarter worth $204,000. RidgeWorth Capital Management LLC bought a new position in shares of La Jolla Pharmaceutical during the first quarter worth $227,000. Finally, Voya Investment Management LLC bought a new position in shares of La Jolla Pharmaceutical during the second quarter worth $243,000.

ILLEGAL ACTIVITY NOTICE: “La Jolla Pharmaceutical Company (LJPC) Stock Price Up 10.3%” was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/30/la-jolla-pharmaceutical-company-ljpc-stock-price-up-10-3.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.